What is WIPO ST.26 and how does it differ from WIPO ST.25?
WIPO ST.26 is a new standard for the presentation of nucleotide and amino acid sequence listings in patent applications. It replaces WIPO ST.25 for applications filed on or after July 1, 2022. The MPEP states: “See MPEP §§ 2412 – 2419 for guidance on WIPO ST.26 requirements for applications filed on or after July 1,…
Read MoreHow do the requirements for sequence listings differ between WIPO ST.25 and WIPO ST.26?
The requirements for sequence listings differ significantly between WIPO ST.25 and WIPO ST.26. WIPO ST.25 was the standard used for applications filed before July 1, 2022, while WIPO ST.26 applies to applications filed on or after that date. The MPEP notes: “See MPEP §§ 2412 – 2419 for guidance on WIPO ST.26 requirements for applications…
Read MoreWhat are the key differences between WIPO ST.25 and the new sequence rules for applications filed after July 1, 2022?
The MPEP 2420 indicates a significant change in the rules governing sequence disclosures in patent applications filed on or after July 1, 2022. The section states: “[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR…
Read MoreWhen did the transition from WIPO ST.25 to WIPO ST.26 occur?
The transition from WIPO ST.25 to WIPO ST.26 for sequence listings in patent applications occurred on July 1, 2022. As stated in MPEP § 2431: “This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” For applications…
Read MoreHow does the change from WIPO ST.25 to ST.26 affect existing patent applications?
The transition from WIPO ST.25 to ST.26 primarily affects new patent applications filed on or after July 1, 2022. As stated in MPEP § 2431: “This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” Existing applications…
Read MoreWhat are the key differences between WIPO ST.25 and WIPO ST.26 for sequence listings?
While MPEP § 2431 doesn’t directly compare WIPO ST.25 and ST.26, it indicates a significant change in requirements: “See MPEP §§ 2412 – 2419 for guidance on WIPO ST.26 requirements for applications filed on or after July 1, 2022.” Key differences include: Format: ST.26 uses XML format, while ST.25 used a text-based format Scope: ST.26…
Read MoreWhat are the WIPO ST.25 sample statements for sequence listings?
The MPEP provides sample language for statements required to support sequence rule submissions under WIPO ST.25. These statements are examples and not exhaustive. They primarily cover three areas: Asserting that the sequence information in the PDF or physical sheets is identical to the computer readable form Stating that amendments adding a sequence listing are supported…
Read MoreWhen are WIPO ST.25 sample statements not applicable?
According to the MPEP, WIPO ST.25 sample statements are not applicable to certain patent applications. Specifically: “This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” For applications filed on or after July 1, 2022, applicants should…
Read MoreWhere can I find a sample sequence listing under WIPO ST.25?
MPEP § 2431 mentions the availability of a sample sequence listing: “A sample ‘Sequence Listing’ is included below.” While the actual sample is not provided in the given excerpt, it’s typically included in the full MPEP section. For the most up-to-date and complete information, including the sample sequence listing, you should refer to the official…
Read MoreWhat are the WIPO ST.25 requirements for nucleotide and amino acid sequence disclosures in patent applications?
WIPO ST.25 requirements for nucleotide and amino acid sequence disclosures in patent applications are outlined in MPEP 2422. These requirements are largely harmonized with USPTO requirements, but there are some key differences: WIPO ST.25 requires that nucleotide sequences containing fewer than 10 specifically defined nucleotides be included in the sequence listing. WIPO ST.25 requires that…
Read More